<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29157273</article-id><article-id pub-id-type="pmc">5697346</article-id><article-id pub-id-type="publisher-id">2307</article-id><article-id pub-id-type="doi">10.1186/s13063-017-2307-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Effect of Daikenchuto (TJ-100) on gastrointestinal symptoms following laparoscopic colectomy in patients with colon cancer: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hoshino</surname><given-names>Nobuaki</given-names></name><address><email>hoshinob@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kawada</surname><given-names>Kenji</given-names></name><address><phone>+81-75-751-3227</phone><email>kkawada@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hida</surname><given-names>Koya</given-names></name><address><email>hidakoya@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Wada</surname><given-names>Toshiaki</given-names></name><address><email>wt0520@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Ryo</given-names></name><address><email>ryotak@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yoshitomi</surname><given-names>Mami</given-names></name><address><email>mystm@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sakai</surname><given-names>Yoshiharu</given-names></name><address><email>ysakai@kuhp.kyoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 2033</institution-id><institution-id institution-id-type="GRID">grid.258799.8</institution-id><institution>Department of Surgery, Graduate School of Medicine, </institution><institution>Kyoto University, </institution></institution-wrap>54 Shogoin- Kawara-cho, Sakyo-ku, Kyoto, 606-8507 Japan </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><elocation-id>553</elocation-id><history><date date-type="received"><day>8</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>2</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Postoperative paralytic ileus can be a difficult complication for both surgeons and patients. Causes and treatments have been discussed for more than two centuries, but have not yet been fully resolved. Daikenchuto (TJ-100, DKT) is a traditional Japanese herbal medicine. Recently, some beneficial mechanisms of DKT to relieve paralytic ileus have been reported. DKT can suppress inflammation, increase intestinal blood flow, and accelerate bowel movements. Therefore, we have designed a randomized controlled trial to investigate the effects of DKT on postoperative gastrointestinal symptoms following laparoscopic colectomy in patients with left-sided colon cancer at a single institution.</p></sec><sec><title>Methods/design</title><p id="Par2">As primary endpoints, the following outcomes will be evaluated: (i) grade of abdominal pain determined using the numeric rating scale (NRS), (ii) grade of abdominal distention determined using the NRS, and (iii) quality of life determined using the Gastrointestinal Quality Life Index (GIQLI). As secondary endpoints, the following will be evaluated: (i) postoperative nutritional status (Onodera&#x02019;s Prognostic Nutritional Index (PNI) and the Controlling Nutritional Status score (CONUT score)), (ii) duration to initial flatus, (iii) duration to initial defecation, (iv) bowel gas volume, (v) character of stool (Bristol Stool Form Scale), (vi) defecation frequency per day, (vii) postoperative complications (Clavien-Dindo classification), (viii) length of postoperative hospital stay, and (ix) metabolites in the stool and blood. This trial is an open-label study, and needs to include 40 patients (20 patients per group) and is expected to span 2&#x000a0;years.</p></sec><sec><title>Discussion</title><p id="Par3">To our knowledge, this is the first randomized controlled trial to investigate the effects of DKT on postoperative subjective outcomes (i.e., postoperative quality of life) following laparoscopic colectomy as primary endpoints. Exploratory metabolomics analysis of metabolites in stool and blood will be conducted in this trial, which previously has only been performed in a few human studies. The study aims to guide a future full-scale pragmatic randomized trial to assess the overall effectiveness of DKT to improve the postoperative quality of life following laparoscopic colectomy.</p></sec><sec><title>Trial registration</title><p id="Par4">UMIN-CTR (Japan), <ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026866">UMIN000023318</ext-link>. Registered on 25 July 2016.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-017-2307-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>TJ-100</kwd><kwd>Laparoscopic colectomy</kwd><kwd>Postoperative gastrointestinal symptoms</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p id="Par12">Postoperative paralytic ileus can be a difficult complication for both surgeons and patients. Causes and treatments have been discussed for more than two centuries, but have not yet been fully resolved [<xref ref-type="bibr" rid="CR1">1</xref>]. The incidence of postoperative ileus following colectomy is reported to be at least 10%, and is considered to be inevitable for patients undergoing abdominal surgeries [<xref ref-type="bibr" rid="CR2">2</xref>]. Patients who suffer from postoperative ileus require additional treatments such as fasting, antibiotics, decompression tubes, or even surgical intervention for suspected bowel strangulation. Owing to this, hospital stays lengthen and medical costs can increase more than 15% [<xref ref-type="bibr" rid="CR2">2</xref>]. Therefore, the prevention of postoperative ileus is crucial for surgeons.</p><p id="Par13">Daikenchuto (TJ-100, DKT) is a traditional Japanese herbal medicine (Kampo). This medicine is a crude drug extract and consists of four active components including processed ginger, ginseng, Japanese zanthoxylum peel and koi (maltose powder). In Japan, DKT has been clinically used for the treatment of postoperative paralytic ileus [<xref ref-type="bibr" rid="CR3">3</xref>]. Recently, some beneficial mechanisms of DKT to relieve paralytic ileus have been reported. DKT can suppress inflammation, increase intestinal blood flow, and accelerate bowel movements [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. The anti-inflammatory effect is derived from inhibited activity of cyclooxygenase-2 and upregulation of endogenous adrenomedullin [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. An increase in intestinal blood flow is due to upregulation of calcitonin gene-related peptide [<xref ref-type="bibr" rid="CR6">6</xref>]. Accelerated bowel movement is due to adjustment of the contraction and relaxation of the intestine by release of acetylcholine, nitric oxide and other excitatory neurotransmitters [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, DKT is considered to be a potential drug to reduce postoperative paralytic ileus and improve postoperative quality of life for patients with colon cancer.</p></sec><sec id="Sec2"><title>Methods/design</title><sec id="Sec3"><title>Objective</title><p id="Par14">The aim of this study is to assess the effect of DKT on postoperative gastrointestinal symptoms following laparoscopic colectomy in patients with left-sided colon cancer.</p></sec><sec id="Sec4"><title>Study design and setting</title><p id="Par15">This study will be conducted at Kyoto University Hospital in Japan, and the design is an open-label randomized controlled trial. This study is expected to span a period of 2&#x000a0;years. Perioperative procedures in both groups will be performed based on the clinical path for laparoscopic colectomy in Kyoto University Hospital. All patients will receive standard bowel preparation (75&#x000a0;mg sodium picosulfate and 12&#x000a0;mg pursennid) and antibiotic prophylaxis (oral doses of 1&#x000a0;g kanamycin and 750&#x000a0;mg metronidazole), and surgical procedures will be conducted by well-experienced, board-certified laparoscopic colorectal surgeons at our institution. Except for the administration of DKT, treatment protocols including perioperative management and surgical procedures will be congruent among the intervention group (DKT group) and the control group (non-DKT group).</p></sec><sec id="Sec5"><title>Endpoints</title><p id="Par16">The following primary endpoints will be evaluated in this clinical trial: (i) grade of abdominal pain determined using the numeric rating scale (NRS), (ii) grade of abdominal distention determined using the NRS, and (iii) quality of life determined using the Gastrointestinal Quality Life Index (GIQLI) [<xref ref-type="bibr" rid="CR9">9</xref>]. NRS measurements of abdominal pain and distention will be taken prior to surgery and at postoperative days (POD) 1, 4, 7, 14 and 28. GIQLI will be taken before surgery and at POD 14 and 28.</p><p id="Par17">The secondary endpoints are (i) postoperative nutritional status (Onodera&#x02019;s prognostic nutritional index (PNI) [<xref ref-type="bibr" rid="CR10">10</xref>] and Controlling Nutritional Status score (CONUT score) [<xref ref-type="bibr" rid="CR11">11</xref>]), (ii) time to initial flatus, (iii) time to initial defecation, (iv) bowel gas volume measured using analysis software, (v) character of stool (Bristol Stool Form Scale [<xref ref-type="bibr" rid="CR12">12</xref>]), (vi) defecation frequency per day, (vii) postoperative complications (Clavien-Dindo classification [<xref ref-type="bibr" rid="CR13">13</xref>]), (viii) duration of postoperative hospital stay, and (ix) metabolomics analysis of metabolites in stool and blood using gas chromatography-tandem mass spectrometry (GC/MS/MS) and liquid chromatography-tandem mass spectrometry (LC/MS/MS) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Schedule of enrolment, intervention, and assessments. GIQLI, Gastrointestinal Quality Life Index</p></caption><graphic xlink:href="13063_2017_2307_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec6"><title>Eligibility criteria</title><p id="Par18">The eligible patients must satisfy the criteria defined below. Potential participants who meet the inclusion criteria will be recruited at outpatient clinics or during preoperative visits before surgery.</p><p id="Par19">Inclusion criteria:<list list-type="order"><list-item><p id="Par20">Patients with left-sided colon cancer (including recto-sigmoid cancer) who are scheduled to undergo laparoscopic surgery</p></list-item><list-item><p id="Par21">Clinical stage I, II and III</p></list-item><list-item><p id="Par22">Patients who suffer from abdominal pain and distention at POD 1 (NRS score &#x02265;1)</p></list-item><list-item><p id="Par23">The European Cooperative Oncology Group (ECOG) performance status of 2 or less.</p></list-item><list-item><p id="Par24">Patients aged 20&#x000a0;years and older at registration</p></list-item><list-item><p id="Par25">Patients who can take medications orally</p></list-item><list-item><p id="Par26">Written informed consent provided to participate in the study</p></list-item></list>
</p><p id="Par27">Exclusion criteria:<list list-type="order"><list-item><p id="Par28">Patients who have history of abdominal surgery or history of bowel obstruction</p></list-item><list-item><p id="Par29">Patients with concomitant inflammatory bowel disease such as ulcerative colitis and Crohn&#x02019;s disease</p></list-item><list-item><p id="Par30">Patients with concomitant endometriosis</p></list-item><list-item><p id="Par31">Patients requiring emergency surgery</p></list-item><list-item><p id="Par32">Patients who have been or will be treated by chemotherapy or radiotherapy</p></list-item><list-item><p id="Par33">Patients with severe comorbidity such as cardiac disease, liver disease, pulmonary disease or renal disease</p></list-item><list-item><p id="Par34">Patients who took Japanese herbal medicine (Kampo) up to 4&#x000a0;weeks prior to registration</p></list-item><list-item><p id="Par35">Patients who took gastrointestinal prokinetic drugs, antipsychotic drugs or antidepressant drugs up to 4&#x000a0;weeks prior to registration</p></list-item><list-item><p id="Par36">Patients with a history of a Kampo allergy in other formulations</p></list-item><list-item><p id="Par37">Patients with hepatitis B or C</p></list-item><list-item><p id="Par38">Patients who are unable to take medications orally at POD 1</p></list-item><list-item><p id="Par39">Patients who are unsuitable for study inclusion as determined by the investigator (e.g., those with severe dementia)</p></list-item></list>
</p></sec><sec id="Sec7"><title>Registration</title><p id="Par40">Patients will be enrolled at POD 1. An eligibility report form will be sent to the registration center (APO PLUS STATION Co., Ltd, Tokyo, Japan). Eligible patients will be centrally randomized to either the DKT group or non-DKT group at the registration center using a computer random number generator with the minimization method for TNM stage, tumor location, and age. Information on the necessary follow-up evaluations will then be sent from the registration center. A flow diagram of this study is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Study flow chart. Investigators obtain informed consent from eligible patients before surgery. Patients are enrolled in the trial, if they can take medicine orally and have abdominal pain and/or distention at postoperative day (POD) 1. Enrolled patients are randomly assigned to either the Daikenchuto (DKT) or non-DKT group</p></caption><graphic xlink:href="13063_2017_2307_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec8"><title>Treatment methods</title><sec id="Sec9"><title>Intervention group: DKT group</title><p id="Par41">DKT (5&#x000a0;g) will be administered orally three times per day between POD 2 and POD 28. DKT manufactured by Tsumura &#x00026; Co (Tokyo, Japan) will be used. We will monitor adherence by checking the number of doses of DKT that are not administered.</p></sec><sec id="Sec10"><title>Control group: non-DKT group</title><p id="Par42">No additional medicine will be administered as a comparator.</p></sec></sec><sec id="Sec11"><title>Prohibited or limited drugs</title><p id="Par43">Prohibited drugs will be drugs that are known to regulate intestinal movement (erythromycin, mosapride citrate, pantethine, panthenol, prostaglandin F2&#x003b1;), digestive enzyme preparations (diastase, pancreatin), anticholinergic drugs (atropine sulfate, scopolamine butylbromide), cathartic drugs (sodium picosulfate), antidiarrheal drugs (albumin tannate, aluminum silicate, dimethicone), antipsychotic drugs (diazepam, flunitrazepam), lactobacillus preparation (lactomin, lactic acid bacteriae, <italic>Clostridium butyriam</italic>), anti-Parkinsonian drugs, and contrast agent (gastrografin).</p><p id="Par44">Limited drugs will be antiemetic drugs including metoclopramide and domperidone. Rescue drugs will be antidiarrheal drugs (magnesium oxides, sennoside), cathartic drugs (loperamide), and analgesic drugs (loxoprofen). If patients use the limited or rescue drugs, investigators will notate the dose and frequency.</p></sec><sec id="Sec12"><title>Criteria for discontinuing the protocol treatment</title><p id="Par45">If grade 3 postoperative adverse effects (Clavien-Dindo classification) are observed, the protocol treatment will be immediately discontinued.</p></sec><sec id="Sec13"><title>Data collection</title><p id="Par46">Prospective data about all patients including physical examination, laboratory data, perioperative clinical information and complications will be collected. Personal information including names and chart numbers will not be collected. Only the study code will be collected and managed separately. The collected data will remain confidential until the investigators analyze the data. The final dataset will be managed by the chief investigator (KK). After the completion of the study, the collected data will be encrypted and stored for 10&#x000a0;years and then discarded. Data collection, management, analysis, and interpretation of data will be performed by the registration center (APO PLUS STATION Co., Ltd).</p></sec><sec id="Sec14"><title>Sample size determination</title><p id="Par47">The sample size calculation is based on a primary endpoint, GIQLI. The GIQLI questionnaire containing 36 questions each with five response categories. The responses to questions are summed to give a numerical score (0&#x02013;128 points). A previous report [<xref ref-type="bibr" rid="CR9">9</xref>] indicates that the mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) change in the GIQLI score between two measurements before and 2&#x000a0;weeks after laparoscopic cholecystectomy in 194 patients was 17&#x02009;&#x000b1;&#x02009;20.7 points. Therefore, the clinically significant mean difference in the GIQLI score is set at 20 with a SD of 20. Using a power level of 80% and a two-sided significance level of 5%, 32 patients (16 patients in each group) are required to show a difference between the DKT and non-DKT groups. Therefore, we determined that 40 patients (20 patients in each group) are needed to endure 20% dropout of patients from this trial.</p></sec><sec id="Sec15"><title>Statistical analysis</title><p id="Par48">All analyses will be performed under the intention-to-treat principle. However, patients will be excluded from the analyses if they are proved to be ineligible after enrollment. Both primary and secondary endpoints will be compared between the DKT group and the non-DKT group. A two-tailed <italic>P</italic> value less than 0.05 is considered statistically significant. For continuous variables, the <italic>t</italic> test will be used when continuous variables follow a normal distribution, whereas the Wilcoxon rank-sum test will be used when continuous variables follow a non-normal distribution. For categorical variables, the chi-square test or Fisher&#x02019;s exact test will be used according to the cell count.</p></sec><sec id="Sec16"><title>Monitoring</title><p id="Par49">This trial is conducted based on Good Clinical Practice. Two people external to trial involvement will check the following at 6&#x000a0;months:<list list-type="order"><list-item><p id="Par50">Informed consent and the data of primary endpoints for all patients</p></list-item><list-item><p id="Par51">Eligibility criteria and hospital stay duration for a sample of 10 patients</p></list-item></list>
</p></sec><sec id="Sec17"><title>Study status</title><p id="Par52">This study is currently collecting data and there has not been any publication on the analysis of the data collected to date.</p></sec></sec><sec id="Sec18"><title>Discussion</title><p id="Par53">This trial will elucidate the effect of DKT on postoperative gastrointestinal symptoms following laparoscopic colectomy in patients with colon cancer. We mainly focus on two important topics: postoperative quality of life and postoperative metabolites in stool and blood.</p><p id="Par54">Although several trials have been conducted, the clinical effectiveness of DKT is still unclear. In previous randomized controlled trials, all primary endpoints were objective outcomes, such as duration to initial flatus and incidence of postoperative paralytic ileus [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. Although some patients were reported to be improved by DKT administration, there has been no report where any subjective outcomes (i.e., postoperative quality of life) are set up as primary endpoints. Assessment of postoperative quality of life has been conducted as a secondary endpoint in some trials, but there was no significant difference between the intervention group and control group [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. This study is the randomized controlled trial to investigate the effects of DKT on postoperative subjective outcomes (i.e., postoperative quality of life) following laparoscopic colectomy as primary endpoints. Moreover, exploratory metabolomics analysis of metabolites in stool and blood will be conducted in this trial. It was reported that DKT could influence the microbiome of stool through bacterial metabolism in animals&#x02019; bowels [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. However, there is no report to date investigating this in humans. Using metabolomics analysis of metabolites in stool and blood, we plan to examine the effect of the intestinal flora by DKT administration, which can lead to the elucidation of the mechanism of DKT in gastrointestinal symptoms and the discovery of the biomarker candidates.</p><p id="Par55">Therefore, we designed this trial to evaluate the effect of DKT on postoperative quality of life and postoperative metabolites in patients with colon cancer undergoing laparoscopic colectomy. The study aims to guide a future full-scale pragmatic randomized trial to assess the overall effectiveness of DKT to improve the postoperative quality of life following laparoscopic colectomy. Methodological rigor, including random allocation and prospective trial registration is aimed at reducing the risk of bias. As a limitation of this study, the possibility of insufficient sample size, bias in the open-label design, and the possibility of unblinding of the assessors to outcome may result in performance bias.</p></sec><sec id="Sec19"><title>Trial status</title><p id="Par56">Recruitment of participants has been ongoing since September 2016.</p></sec></body><back><app-group><app id="App1"><sec id="Sec20"><title>Additional file</title><p id="Par63">
<media position="anchor" xlink:href="13063_2017_2307_MOESM1_ESM.doc" id="MOESM1"><label>Additional file 1:</label><caption><p>SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 123&#x000a0;kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>CONUT</term><def><p id="Par5">Controlling nutritional status</p></def></def-item><def-item><term>DKT</term><def><p id="Par6">Daikenchuto</p></def></def-item><def-item><term>GIQLI</term><def><p id="Par7">Gastrointestinal Quality Life Index</p></def></def-item><def-item><term>NRS</term><def><p id="Par8">Numeric rating scale</p></def></def-item><def-item><term>PNI</term><def><p id="Par9">Prognostic nutritional index</p></def></def-item><def-item><term>POD</term><def><p id="Par10">Postoperative day</p></def></def-item><def-item><term>SD</term><def><p id="Par11">Standard deviation</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13063-017-2307-7) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par57">This study was supported by a research grant from Tsumura &#x00026; Co, Tokyo, Japan.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par58">Requested data for public purpose or research transparency will be provided on reasonable request (please contact the corresponding author).</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>KK and YS conceived the study. KK and KH initiated the study design and drafted the protocol. NH, TW, RT, MY, and YS contributed to the refinement of the study protocol. NH and KK prepared the first draft of the manuscript. KH, TW, RT, MY, and YS critically reviewed, revised and approved the final version. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par59">This protocol has been prepared in accordance with Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), a completed SPIRIT checklist is included as Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p><p>This study protocol has been conducted according to the Declaration of Helsinki, and was approved by the institutional review board of Kyoto University, Kyoto, Japan (C1112-1) and by the institutional review board of Tsumura &#x00026; Co, Tokyo, Japan (1502). Participation in the trial never influences the therapeutic strategy and treatment burden. Written informed consent will be obtained from all participants by the investigator.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par60">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par61">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par62">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augestad</surname><given-names>KM</given-names></name><name><surname>Delaney</surname><given-names>CP</given-names></name></person-group><article-title>Postoperative ileus: impact of pharmacological treatment, laparoscopic surgery and enhanced recovery pathways</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>2067</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i17.2067</pub-id><pub-id pub-id-type="pmid">20440846</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>S</given-names></name><name><surname>Saunders</surname><given-names>WB</given-names></name><name><surname>Stemkowski</surname><given-names>S</given-names></name></person-group><article-title>Economic burden of postoperative ileus associated with colectomy in the United States</article-title><source>J Manag Care Pharm</source><year>2009</year><volume>15</volume><fpage>485</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">19610681</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itoh</surname><given-names>T</given-names></name><name><surname>Yamakawa</surname><given-names>J</given-names></name><name><surname>Mai</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Kanda</surname><given-names>T</given-names></name></person-group><article-title>The effect of the herbal medicine dai-kenchu-to on post-operative ileus</article-title><source>J Int Med Res</source><year>2002</year><volume>30</volume><fpage>428</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1177/147323000203000410</pub-id><pub-id pub-id-type="pmid">12235926</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>T</given-names></name><name><surname>Kase</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Ishige</surname><given-names>A</given-names></name><name><surname>Komatsu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of Dai-kenchu-to on intestinal obstruction following laparotomy</article-title><source>J Smooth Muscle Res</source><year>1999</year><volume>35</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1540/jsmr.35.47</pub-id><pub-id pub-id-type="pmid">10463435</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Omiya</surname><given-names>Y</given-names></name><name><surname>Hira</surname><given-names>Y</given-names></name><name><surname>Kaneko</surname><given-names>A</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn&#x02019;s disease rat model</article-title><source>J Gastroenterol</source><year>2011</year><volume>46</volume><fpage>1187</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s00535-011-0438-2</pub-id><pub-id pub-id-type="pmid">21808981</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>T</given-names></name><name><surname>Koseki</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Ebisawa</surname><given-names>Y</given-names></name><name><surname>Chisato</surname><given-names>N</given-names></name><name><surname>Iwamoto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Colonic vascular conductance increased by Daikenchuto via calcitonin gene-related peptide and receptor-activity modifying protein 1</article-title><source>J Surg Res</source><year>2008</year><volume>150</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2008.02.057</pub-id><pub-id pub-id-type="pmid">18561951</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Mantyh</surname><given-names>C</given-names></name><name><surname>Ludwig</surname><given-names>K</given-names></name><name><surname>Pappas</surname><given-names>TN</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>The herbal medicine, Dai-Kenchu-to, accelerates delayed gastrointestinal transit after the operation in rats</article-title><source>J Surg Res</source><year>2006</year><volume>131</volume><fpage>290</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2005.09.018</pub-id><pub-id pub-id-type="pmid">16259999</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kito</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name></person-group><article-title>Effects of Dai-kenchu-to on spontaneous activity in the mouse small intestine</article-title><source>J Smooth Muscle Res</source><year>2006</year><volume>42</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1540/jsmr.42.189</pub-id><pub-id pub-id-type="pmid">17435378</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eypasch</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>JI</given-names></name><name><surname>Wood-Dauphinee</surname><given-names>S</given-names></name><name><surname>Ure</surname><given-names>BM</given-names></name><name><surname>Schm&#x000fc;lling</surname><given-names>C</given-names></name><name><surname>Neugebauer</surname><given-names>E</given-names></name><etal/></person-group><article-title>Gastrointestinal Quality of Life Index: development, validation and application of a new instrument</article-title><source>Br J Surg</source><year>1995</year><volume>82</volume><fpage>216</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/bjs.1800820229</pub-id><pub-id pub-id-type="pmid">7749697</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onodera</surname><given-names>T</given-names></name><name><surname>Goseki</surname><given-names>N</given-names></name><name><surname>Kosaki</surname><given-names>G</given-names></name></person-group><article-title>Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients</article-title><source>Nihon Geka Gakkai Zasshi</source><year>1984</year><volume>85</volume><fpage>1001</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6438478</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignacio de Ulibarri</surname><given-names>J</given-names></name><name><surname>Gonzalez-Madrono</surname><given-names>A</given-names></name><name><surname>de Villar</surname><given-names>NG</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>P</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>B</given-names></name><name><surname>Mancha</surname><given-names>A</given-names></name><etal/></person-group><article-title>CONUT: a tool for controlling nutritional status. First validation in a hospital population</article-title><source>Nutr Hosp</source><year>2005</year><volume>20</volume><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15762418</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>SJ</given-names></name><name><surname>Heaton</surname><given-names>KW</given-names></name></person-group><article-title>Stool form scale as a useful guide to intestinal transit time</article-title><source>Scand J Gastroenterol</source><year>1997</year><volume>32</volume><fpage>920</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3109/00365529709011203</pub-id><pub-id pub-id-type="pmid">9299672</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavien</surname><given-names>PA</given-names></name><name><surname>Barkun</surname><given-names>J</given-names></name><name><surname>de Oliveira</surname><given-names>ML</given-names></name><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Dindo</surname><given-names>D</given-names></name><name><surname>Schulick</surname><given-names>RD</given-names></name><etal/></person-group><article-title>The Clavien-Dindo classification of surgical complications: five-year experience</article-title><source>Ann Surg</source><year>2009</year><volume>250</volume><fpage>187</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181b13ca2</pub-id><pub-id pub-id-type="pmid">19638912</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>M</given-names></name><name><surname>Morine</surname><given-names>Y</given-names></name><name><surname>Nagano</surname><given-names>H</given-names></name><name><surname>Hatano</surname><given-names>E</given-names></name><name><surname>Kaiho</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001)</article-title><source>Int J Clin Oncol</source><year>2015</year><volume>20</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/s10147-014-0678-2</pub-id><pub-id pub-id-type="pmid">24595550</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akamaru</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Nishida</surname><given-names>T</given-names></name><name><surname>Omori</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>K</given-names></name><name><surname>Mikata</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of daikenchuto, a Japanese herb, on intestinal motility after total gastrectomy: a prospective randomized trial</article-title><source>J Gastrointest Surg</source><year>2015</year><volume>19</volume><fpage>467</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s11605-014-2730-y</pub-id><pub-id pub-id-type="pmid">25564322</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsuno</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kaiho</surname><given-names>T</given-names></name><name><surname>Kunieda</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902)</article-title><source>Jpn J Clin Oncol</source><year>2015</year><volume>45</volume><fpage>650</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyv056</pub-id><pub-id pub-id-type="pmid">25972515</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>M</given-names></name><name><surname>Wakabayashi</surname><given-names>G</given-names></name><name><surname>Ishida</surname><given-names>K</given-names></name><name><surname>Kaiho</surname><given-names>T</given-names></name><name><surname>Kitagawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of daikenchuto, a traditional Japanese herbal medicine, after total gastrectomy for gastric cancer: a multicenter, randomized, double-blind, placebo-controlled, Phase II Trial</article-title><source>J Am Coll Surg</source><year>2015</year><volume>221</volume><fpage>571</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2015.03.004</pub-id><pub-id pub-id-type="pmid">26141466</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Kawai</surname><given-names>M</given-names></name><name><surname>Hirono</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Kodera</surname><given-names>Y</given-names></name><name><surname>Sho</surname><given-names>M</given-names></name><etal/></person-group><article-title>Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: a multicenter, double-blind, randomized, placebo-controlled trial</article-title><source>Surgery</source><year>2016</year><volume>159</volume><fpage>1333</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2015.11.019</pub-id><pub-id pub-id-type="pmid">26747224</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>K</given-names></name><name><surname>Shimada</surname><given-names>M</given-names></name><name><surname>Kuwahara</surname><given-names>T</given-names></name><name><surname>Hirakawa</surname><given-names>H</given-names></name><name><surname>Kurita</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effect of Kampo medicine &#x0201c;Dai-kenchu-to&#x0201d; on microbiome in the intestine of the rats with fast stress</article-title><source>J Med Invest</source><year>2013</year><volume>60</volume><fpage>221</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2152/jmi.60.221</pub-id><pub-id pub-id-type="pmid">24190039</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasebe</surname><given-names>T</given-names></name><name><surname>Ueno</surname><given-names>N</given-names></name><name><surname>Musch</surname><given-names>MW</given-names></name><name><surname>Nadimpalli</surname><given-names>A</given-names></name><name><surname>Kaneko</surname><given-names>A</given-names></name><name><surname>Kaifuchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K</article-title><source>Pharmacol Res Perspect</source><year>2016</year><volume>4</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/prp2.215</pub-id></element-citation></ref></ref-list></back></article>